Gyre Therapeutics (GYRE) Institutional Ownership $9.45 -0.31 (-3.14%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Gyre Therapeutics (NASDAQ:GYRE)CurrentInstitutional OwnershipPercentage23.99%Number ofInstitutional Buyers(last 12 months)15TotalInstitutional Inflows(last 12 months)$4.51MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$444.18K Get GYRE Insider Trade Alerts Want to know when executives and insiders are buying or selling Gyre Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data GYRE Institutional Buying and Selling by Quarter Gyre Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/29/2025 Bank of New York Mellon Corp16,492$127K0.0%+18.7%0.018% 4/7/2025 GAMMA Investing LLC1,822$140K0.0%+15,083.3%0.002% 2/17/2025Bank of America Corp DE6,937$84K0.0%+40.4%0.007% 2/14/2025Northern Trust Corp103,382$1.25M0.0%+9.1%0.111% 2/13/2025Barclays PLC10,543$128K0.0%+13.5%0.011% 2/13/2025Wells Fargo & Company MN4,016$49K0.0%+29.4%0.004% 2/11/2025Advantage Alpha Capital Partners LP8,873$107K0.0%-66.7%0.009% 2/6/2025Charles Schwab Investment Management Inc.114,566$1.39M0.0%+0.8%0.123% 2/6/2025SBI Securities Co. Ltd.101,239$1.23M0.0%N/A0.108% 2/4/2025 Bank of New York Mellon Corp13,896$168K0.0%+11.1%0.015% 11/19/2024Barclays PLC9,288$116K0.0%+281.8%0.010% 11/16/2024Geode Capital Management LLC303,647$3.81M0.0%+16.9%0.325% 11/15/2024Barclays PLC9,288$116K0.0%+281.8%0.010% 11/15/2024State Street Corp104,490$1.31M0.0%+8.8%0.112% 11/13/2024FMR LLC3,742$47K0.0%N/A0.004% 11/13/2024Advantage Alpha Capital Partners LP26,634$334K0.1%N/A0.029% 11/12/2024Charles Schwab Investment Management Inc.113,648$1.43M0.0%+392.2%0.122% 8/14/2024Marshall Wace LLP10,720$128K0.0%-58.0%0.013% 8/9/2024Renaissance Technologies LLC13,900$166K0.0%N/A0.016% 8/9/2024WINTON GROUP Ltd18,467$220K0.0%N/A0.022% 8/1/2024 Rhumbline Advisers10,291$123K0.0%N/A0.012% 7/26/2024 Bank of New York Mellon Corp18,266$218K0.0%N/A0.021% 5/10/2024Vanguard Group Inc.195,098$3.41M0.0%-1.5%0.228% (Data available from 1/1/2016 forward) GYRE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of GYRE shares? During the previous two years, 17 institutional investors and hedge funds held shares of Gyre Therapeutics. The most heavily invested institutionals were Geode Capital Management LLC ($3.81M), Vanguard Group Inc. ($3.41M), Charles Schwab Investment Management Inc. ($1.39M), State Street Corp ($1.31M), Northern Trust Corp ($1.25M), SBI Securities Co. Ltd. ($1.23M), and WINTON GROUP Ltd ($220K).Learn more on GYRE's institutional investors. What percentage of Gyre Therapeutics stock is owned by institutional investors? 23.99% of Gyre Therapeutics stock is owned by institutional investors. Learn more on GYRE's institutional investor holdings. Which institutional investors have been buying Gyre Therapeutics stock? Of the 15 institutional investors that purchased Gyre Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: SBI Securities Co. Ltd. ($101.24K), Charles Schwab Investment Management Inc. ($91.48K), Geode Capital Management LLC ($43.84K), Advantage Alpha Capital Partners LP ($26.63K), Bank of New York Mellon Corp ($22.25K), WINTON GROUP Ltd ($18.47K), and Barclays PLC ($14.97K). How much institutional buying is happening at Gyre Therapeutics? Institutional investors have bought a total of 368,559 shares in the last 24 months. This purchase volume represents approximately $4.51M in transactions. Which Gyre Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Gyre Therapeutics stock in the last 24 months: Advantage Alpha Capital Partners LP ($17.76K), Marshall Wace LLP ($14.82K), and Vanguard Group Inc. ($3.00K). How much institutional selling is happening at Gyre Therapeutics? Institutional investors have sold a total of 35,584 shares in the last 24 months. This volume of shares sold represents approximately $444.18K in transactions. Related Companies Organon & Co. Institutional Ownership Merus Institutional Ownership Crinetics Pharmaceuticals Institutional Ownership SpringWorks Therapeutics Institutional Ownership Akero Therapeutics Institutional Ownership Viking Therapeutics Institutional Ownership Xenon Pharmaceuticals Institutional Ownership Catalyst Pharmaceuticals Institutional Ownership MorphoSys Institutional Ownership Protagonist Therapeutics Institutional Ownership This page (NASDAQ:GYRE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GYRE Stock Free GYRE Stock Alerts